| 0 (0%) | 08-26 06:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.97 | 1-year : | 18.93 |
| Resists | First : | 11.96 | Second : | 16.2 |
| Pivot price | 7.96  |
|||
| Supports | First : | 5.09 | Second : | 4.24 |
| MAs | MA(5) : | 7.59 |
MA(20) : | 7.77 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -1.8  |
Signal : | -2.1 |
| %K %D | K(14,3) : | 13.9 |
D(3) : | 33.1 |
| RSI | RSI(14): 36.4 |
|||
| 52-week | High : | 33 | Low : | 5.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AMKL ] has closed above bottom band by 12.2%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 6.94 - 6.99 | 6.99 - 7.03 |
| Low: | 6.26 - 6.32 | 6.32 - 6.37 |
| Close: | 6.45 - 6.54 | 6.54 - 6.6 |
Tue, 05 May 2026
Defiance Launches AMKL: The First Daily 2X Long ETF for Amkor Technology, Inc. - GlobeNewswire
Sun, 29 Mar 2026
Acute Megakaryoblastic Leukemia With Myeloid Sarcoma in the Temporal Bone: A Case Report - Cureus
Thu, 08 Jan 2026
Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia - Nature
Mon, 29 Dec 2025
Enhancer-driven epigenetic rewiring in CBFA2T3-GLIS2 pediatric leukemia - EurekAlert!
Thu, 28 Aug 2025
Yale Study: Potential Treatment Pathway Found for Rare and Aggressive Leukemia - Yale School of Medicine
Fri, 01 Aug 2025
The RBM39 degrader indisulam inhibits acute megakaryoblastic leukemia by altering the alternative splicing of ZMYND8. - Physician's Weekly
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|